Context

Following the Federal Government’s decision to prohibit the importation of key medicines—including paracetamol and metronidazole—alongside broader restrictions across agriculture, consumer goods, and industrial inputs, what are the expected short- to medium-term effects on prices, supply stability, and public health outcomes? In particular, how might constraints in domestic manufacturing capacity, potential supply inelasticities, and quality assurance challenges shape market equilibrium in the pharmaceutical sector? Additionally, to what extent could this policy generate import substitution gains versus welfare losses, especially for low-income households dependent on affordable essential drugs? Finally, what complementary policies—such as subsidies, capacity expansion incentives, or regulatory reforms—would be necessary to mitigate transitional shocks and ensure that the shift toward local production yields net positive economic outcomes?